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Abstract
Purpose of Review The aim was to review evidence about diabetes secondary to hereditary pancreatitis, seeking novel diagnostic
and treatment features.
Recent Findings Hereditary pancreatitis (HP) is an autosomal dominant condition, characterized by recurrent episodes of acute
pancreatitis, progression to fibrosis, and chronic pancreatitis. Clinical presentation includes diabetes of the exocrine pancreas
(DEP). HP prevalence ranges from 0.3 to 0.57 per 100,000 people, with up to 80% of these develop DEP. This condition often
requires specific interventions: with regard to metabolic control, metformin is the first choice for those with mild DEP, and for
those in advanced disease, insulin is considered the first-line therapy. Insulin analogues and insulin pump therapy are preferred
due to the brittle glycemic pattern and risk of hypoglycemia. In case of exocrine insufficiency, pancreatic enzyme replacement
therapy is recommended. Pancreatic polypeptide administration is a promising novel treatment feature.
Summary DEP due to HP appears to be a misdiagnosed condition. The requirement of specific management demonstrates the
importance of this matter; therefore, appropriate recognition and classification are important.
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Introduction
Hereditary pancreatitis (HP) is an autosomal dominant condi-
tion, with an estimated penetrance of 80%. It is a rare disease
characterized by recurrent episodes of acute pancreatitis, pro-
gression to fibrosis, and chronic pancreatitis (CP) [1••]. The
first HP report was in 1952 by Comfort and Steinberg, who
suggested a genetic background [2].
It was only in 1996 that an associated genetic mutation,
R122H, was identified by Whitcomb et al. in the cationic
trypsinogen gene (PRSS1) [3]. In the following years, several
PRSS1 mutations and diverse HP related genes were discov-
ered, specifically the serine protease inhibitor Kazal type 1
(SPINK1), the cystic fibrosis transmembrane conductance
regulator (CFTR), the chymotrypsin C (CTRC) [4–7], and
the carboboxypeptidase A1 (CPA1) [4, 8].
The clinical presentation of HP includes abdominal pain,
malabsorptive syndrome due to pancreatic exocrine dysfunc-
tion, and diabetes mellitus (DM) due to islet cell damage [9].
Diabetes mellitus caused by exocrine insufficiency used to be
called by pancreatogenic DM or type 3c diabetes (T3cDM)
[10] notwithstanding more recently the medical literature re-
fers to it as diabetes of the exocrine pancreas (DEP) [11]. DEP
encompasses diverse causes with CP the most common, al-
though pancreatic ductal adenocarcinoma and cystic fibrosis
are equally of importance [12].
Diabetes is an independent risk factor of mortality in these
patients, with micro and macrovascular damage caused by
DEP being a significant late sequelae of CP [13]. While the
prevalence of DM is estimated to be 9.3% in the US general
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population [14], in CP patients it is up to about 80% [14, 15],
which demonstrates the importance of this matter.
Therefore, this article aims to review the literature on DEP
and its relationship to hereditary pancreatitis.
Epidemiology
There is currently insufficient data to precisely estimate the
prevalence of DEP due to HP [15, 16]. In addition to the small
number of studies performed in this condition, DEP is also
underestimated and underdiagnosed, making estimation of
worldwide prevalence challenging [17].
Chronic pancreatitis is a major cause of DEP (25–80%)
[18••, 19] with an incidence of 9.62 cases per 100,000
person-years [20]. Due to the difficulty in diagnosing CP,
the prevalence of CP has been conservatively estimated to
be as high as 120–143 per 100,000 individuals [21].
Adopting cohorts with diabetes to estimate DEP prevalence,
it is acceptable to assume that this ranges from 5 to 10% in a
population of individuals with diabetes [12]. Moreover, HP is
an underestimated cause of CP, with up to 32% of idiopathic
chronic pancreatitis having underlying genetic mutations [22].
HP has an estimated prevalence that varies greatly depending
on the region, between 0.3 to 0.57 per 100,000 according to
national cohort data [22, 23].
Analyzing several HP regional studies, there are significant
variation in epidemiological data. The discrepancy is more no-
table in PRSS1mutation percentage, which ranges from 10.5 to
67.5, and is directly influenced by the different clinical criteria
used to determine genetic testing. The lack of a uniform diag-
nostic criteria leads to heterogeneous samples and may also
explain discordant diabetes rates, median time to DEP, and
cumulative risk of DM found in these series (Table 1).
Genetics
Since 1996, when the first genetic association was de-
scribed, more than 35 mutations of PRSS1 were discovered
[30, 31]. This autosomal-dominant gene mutation pattern,
found in 65–100% of hereditary pancreatitis kindreds [16],
is associated with an increase of autocatalytic conversion
of trypsinogen to active trypsin (Fig. 1) [32]. This abnor-
mal intrapancreatic process is responsible for the progres-
sive destruction of acinar cells, resulting in ductal and in-
terstitial injury [4]. The most common PRSS1 mutations
(R122H and N29I) are those associated with gain of func-
tion, responsible for enhancing trypsinogen autoactivation,
and increasing trypsin stability [33, 34].
In contrast, SPINK1 is responsible for controlling intra
pancreatic trypsin 1 activity, revealing itself as the first line
of defense against this abnormal conversion. It represents a
loss of function mutation with a recessive inheritance pattern
that results in a decreased trypsin degradation [35]. Facing
SPINK1’s inheritance model, in which less than 1% of the
carriers develop CP, it was proposed a complex pathophysiol-
ogy participation of gene-environment and gene-gene interac-
tions [36]. These genetic mutations build a high-risk model
that might help explain disparate CP susceptibilities in alco-
holic and tropical pancreatitis diseases [36, 37].
Other genetic defects are also involved, such as CTRC,
which is responsible for all human trypsin and trypsinogen
degradation [38], yet CTRC mutation appears to be a low-
risk factor [6]. In other hand, CFTR may cause cystic fibrosis
in severe mutation cases [39]; it is also a loss function gene,
reducing bicarbonate conductance [40]. A number of distinct
genes have recently been related to HP: CPA1 due to endoplas-
mic reticulum stress [41], CTSB due to a suppositional prema-
ture trypsin activation [42], and CLDN2 and CASR which
pathological implications are currently unknown [43, 44].
Table 1 Epidemiological and clinical data based on HP regional series
















USA 717 – 67 – – –
Keim et al/2001 [25] Germany 550 – 18.4 24 – –
Howes et al/2004* [1] Europe 527 – 81 32 53 47.6
Masamune et al/2017 [26] Japan 271 0.35 41 21.6 58 36
Rebours et al/2008 [23] France 200 0.3 67.5 26 38 –
Joergensen et al/2010 [22] Denmark 122 0.57 14.8 32 – –
Räty et al/2007 [27] Finland 36 – 22 0 – –
Palaez-Luna et al/2014 [28] Mexico 19 – 10.5 5 – –
Dytz et al/2015 [29] Brazil 16 – 62.5 31.3 – –
*On behalf of the European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC)
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Pathophysiology
Chronic pancreatitis is marked by recurrent acute episodes
inducing severe damage to the endocrine and exocrine paren-
chyma, which may lead to their respective pancreatic insuffi-
ciencies [45]. An inflammatory pattern is observed in all types
of events which induce exocrine injuries, causing increased
intracellular levels of activated pancreatic enzymes. In the
long term, there is an ongoing damage to the pancreas via
oxidative stress [46].
Exocrine insufficiency due to progression of inflammatory
and fibrotic processes occurs in up to 37% of the patients with
HP at 50 years of age [1••] and owing to the large pancreatic
reserve available; pancreatic exocrine insufficiency only oc-
curs when more than 90% of exocrine function is lost [47].
Malabsorptive syndrome is one of the most important HP’s
clinical repercussion, and it is also significantly associated
with a higher mortality [48].
Endocrine insufficiency is observed in up to 47% of the
patients with HP at 50 years and 79% at 80 years [1••].
Although continuous damage to the islet cells is parallel with
the exocrine degradation, overt diabetes occurs later in DEP
[49]. The DEP’s pathology basis is endogenous insulin defi-
ciency, due to initially an inflammatory environment and β-
cells dysfunction, followed by significant β-cells loss caused
by progressive fibrosis [50••].
Aside from β-cells loss, there is also fundamental α-cells
dysfunction resulting in counter regulatory hormone deficien-
cy. Lack of glucagon counter-regulatory response is a signif-
icant contributor to glycemic lability, and variability frequent-
ly observed in these patients [50••]. Lack of coordinated di-
gestion and absorption, diminished paracrine, and endocrine
factors as well as impaired activation of hepatic gluconeogen-
esis are other mechanisms also associated to the brittle diabe-
tes glycemic patterns pathophysiology [17]. Hypoglycemic
excursions in the context of increased glycemic variability is
a major clinical endpoint of the aforementioned mechanisms
and is an important risk factor of increased mortality [51••].
Deficiency of pancreatic polypeptide (PP) response may
also play a key role in hepatic insulin resistance [52]. PP is a
glucoregulatory hormone that regulates the expression of in-
sulin receptors which modulate hepatic insulin sensitivity re-
sponse [53]. Therefore, DEP appears to also be an indepen-
dent risk factor contributing to increased peripheral insulin
resistance and diabetes [54].
Clinical Aspects
HP is distinguished by an early age of onset; the primary
manifestation is usually acute pancreatitis at 10–12 years
[1••, 23], although in some studies the median age was even
earlier [55, 56]. The evolution to exocrine insufficiency most-
ly occurs at second or third decade of life, when epigastric
abdominal pain becomes the most common symptom, which
might be followed by exocrine pancreatic insufficiency syn-
drome including abdominal cramps, fatty stools associated
with steatorrhea, and malnutrition [57].
The overall median onset age of DEP due to HP is estimat-
ed to be 53 years [1••]; paradoxically, DEP can sometimes be
the primary presentation of HP [58]. Its duration does not
appear to be influenced by mutation status or gender [1••,
26]. Notwithstanding, DEP is generally reported as a brittle
disease; there is a lack of data about rates of hypoglycemia in
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DEP [18••, 58]. Available data suggest that episodic non-
severe hypoglycemia occurs in up to 79% of patients with
pancreatogenic diabetes, and severe hypoglycemia occurs in
up to 41% [59]. The reported increased risk of hypoglycemia
is associated with increased mortality [60].
There are also exiguous data about metabolic control in
DEP especially due to HP [15]. A Brazilian cohort study dem-
onstrated high rates of hypoglycemia and capillary blood glu-
cose variability in patients with DM associated with HP [61].
Another study compared glycemic variability (GV) between
DEP and T2DM, with higher GVand rates of hyperglycemia
observed in the DEP group [62]. Even with high glucose
levels, these patients rarely present ketoacidosis, probably be-
cause of the remaining β-cells function, in which absolute
insulin deficiency is uncommon [63, 64].
Diagnosis
Diabetes mellitus in the context of disease of the exocrine
pancreas is not commonly recognized by physicians; its diag-
nosis might be challenging, specially due to a lack of defini-
tive criteria, what should be the explanation of the fact that the
most cases are initially misdiagnosed as T2DM. Edwald and
Bretzel propose the following criteria for DEP secondary to
CP (Table 2) [18••]:
These criteria might be helpful, however, have been criti-
cized for the laboriousness of applying them to all clinical
settings [65]. For the American Diabetes Association (ADA)
recommendations, there are no specific diagnostic criteria for
DEP. Even though, the use of the above mentioned major
criteria is encouraged by the association as a distinguishing
feature [11].
The most commonly used criteria for HP was defined by
European Registry of Hereditary Pancreatitis and Pancreatic
Cancer (EUROPAC) trial and is made on basis of two first-
degree relatives, or three or more second-degree relatives, in
two or more generations with recurrent acute pancreatitis and/
or CP, for which there were no predisposing factors [1••].
Once HP diagnosis is made, diabetes (or prediabetes) screen-
ing might be performed annually with random glucose,
HbA1c, and/or oral glucose tolerance test (OGTT) [50••,
58]. This investigation is crucial since it is observed a substan-
tial increase in diabetes prevalence with longer duration of HP
[66].
Despite the DEP diagnostic proposal criteria, in usual clin-
ical practice, DM patients who present with malabsorptive
syndrome associated to episodes of acute pancreatitis and a
glycemic brittleness hard to control should raise clinical sus-
picions of DEP. A history of recurrent unexplained attacks of
acute pancreatitis, unexplained chronic pancreatitis episode
with or without a positive family history, as a well as CP
episodes in children should instigate investigation for HP,
mainly in DM patients. Thus, more studies are needed to de-
fine clinical and characteristic features with reasonable sensi-
tivity and specificity for diagnosis of DEP related to HP.
Management
DEP often requires specific interventions [67]. As insulin defi-
ciency is a key pathophysiological feature of DEP, insulin is
considered first line therapy for most patients with advanced
disease [68]. The initial dose calculation of insulin therapy
should follow those on multiple daily injections (MDI) in
T1DM [50••]. Despite of the side effects, such increasing risk
of pancreatic cancer, with an odds ratio of 2.78 and hazard ratio
of cancer-related mortality of 1.9 (p < 0.05) [69, 70], insulin
remains the preferred treatment especially during acute epi-
sodes of pancreatitis as well in hospitalized and malnourished
patients, in which the anabolic insulin effects are desired [50••].
Insulin therapy presents a risk of hypoglycemia notedly for
those with an increased peripheral insulin sensitivity [71]. The
labile glycemic control is the reason why glucose levels
should be slightly upward the normal targets, as HbA1c <
7%, aiming to improve the quality of life [72, 73]. Providing
DM structured education programs is important to achieve




Major criteria (all must be present)
• A diagnosis of diabetes mellitus.
• Evidence of exocrine pancreatic insufficiency (according to the monoclonal fecal elastase-1 test or direct function tests).
• Pathological pancreatic imaging (endoscopic ultrasound, magnetic resonance imaging, or computed tomography).
• Absence of type 1 diabetes mellitus associated autoimmune markers.
Minor criteria
• Impaired beta cell function (e.g., HOMA-B, C-peptide/glucose-ratio).
• No excessive insulin resistance (e.g., HOMA-IR).
• Impaired incretin secretion (e.g.GLP-1, pancreatic polypeptide).
• Low serum levels of lipid soluble vitamins (A, D, E, and K).
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intake [74]. These planned and graded process should facili-
tate the knowledge, skills, and ability for diabetes self-
management by enhancing health-promoting behaviors and
empower people with DM to implement flexible intensive
insulin therapy [75].
Some treatment approaches may also be considered aiming
to reduce the risk of hypoglycemia, such the insulin analogues
and insulin pump therapy [50••, 61]. Recently, the use of the
real-time continuous glucose monitoring (RT-CGM) for peo-
ple with type 1 diabetes treated with MDI have been shown to
be effective in improving glycemic control and reducing the
risk of hypoglycemia [76]. RT-CGMmight represent a change
management approach for patients with problematic hypogly-
cemia, such DEP patients, since markedly improves HbA1C
and glycemic variability indices, as well as reduces the num-
ber of hypoglycemic excursions. It is reasonable that RT-
CGM benefits can be extended to DEP patients treated with
MDI, representing high clinical relevance, especially for those
who are unable to use insulin pumps [77].
Additional features may be held intending to improve the
metabolic control of these patients. Coefficient of variation
(CV), considered the main acceptable measure of glycemic
variability, and standard deviation (SD) have been commonly
used as glycemic variability indices. Both CV and SD are
obtained using continuous glucose monitoring measures.
These are robust features which use should improve glycemic
control while avoiding hypoglycemia [78]. Their clinical ap-
plication is supported by the fact that HbA1c is a poor predic-
tor of hypoglycemic episodes, specially the silent ones, where-
as low GV represents trustingly a low risk of severe hypogly-
cemia [79, 80].
In those with mild severity of DM (HbA1c < 8%), oral
hypoglycemic agents might be considered [50••]. Metformin
should be the first choice; besides of the convenience of using
an oral agent, this drug offers a theoretical anti-neoplastic
effect, decreasing the risk of pancreatic ductal adenocarcino-
ma [69, 81]. Nevertheless, it also causes weight loss and im-
portant gastrointestinal adverse effects that need to be tolerat-
ed [50••]. A second-line therapy is the thiazolidinediones
(TZD); these drugs appear to improve the hepatic and periph-
eral insulin sensitivities in experimental studies [82].
However, TZD should only be recommended considering
the possible impact of their side effects, especially the risk of
fracture and congestive heart failure [83].
Incretin-based therapies, including glucagon-like peptide-1
(GLP-1) analogues and oral dipeptidyl peptidase-4 inhibitors,
are not commonly recommended. Notwithstanding enhancing
insulin secretion, these drugs are associated with a hypothet-
ical increased risk of drug-induced pancreatitis and pancreatic
cancer [84]. In the same way, sodium-glucose cotransporter 2
inhibitors (SGLT2) should be avoided due to the lack of data
in this context, as well as the important side effects such risk of
dehydration and weight loss [85].
The primary medical nutrition therapy goals should include
preventing or treating malnutrition, controlling symptoms of
steatorrhea, and minimizing meal induced hyperglycemia
[50••]. In case of exocrine insufficiency of any degree to pre-
scribe pancreatic enzyme replacement therapy (PERT) is rec-
ommended. This replacement aims to increase postprandial
response, enable the absorption of vitamin D, and to prevent
A, D, E, and K vitamins deficiency [86]. PERTand vitamin D
replacement are critical to prevent metabolic bone disease and
osteoporosis in these patients [87].
DEP glucose levels are usually reported as difficult to con-
trol. Facing this struggle, PP administration reveals itself as a
promising novel feature. Several studies showed that PP ther-
apy reversed the hepatic insulin resistance, enabled effective
utilization of circulating insulin, and improved glycemic con-
trol, decreasing insulin requirements in DEP patients [52,
88–90]. Whether it is available, a semester screening of pan-
creatic polypeptide response might be helpful, if reduced
would assist in early identification of impaired pancreatic en-
docrine function, and consequent increased risk of diabetes in
HP patients with CP [91].
Moreover, total pancreatectomywith islet autotransplantation
(TPIAT) might be an option in patients with severe complica-
tions, suffering refractory abdominal pain, or in those with high
risk of pancreatic cancer. This endocrine function-preserving
autologous islet cell isolation and re-implantationmethod cannot
be considered a prevention nor a treatment for diabetes. The
primary objective of this surgical approach is the pain relieving
[51••]. Therefore, in selected patients, TPIAT has been shown to
be effective in restoring the quality of life, as well as improving
the glycemic control [92].
Complications
DM and CP are both independent risk factors for pancreatic
ductal adenocarcinoma; therefore, there is no doubt that this
combination, present in people with DEP, represents a signif-
icant increased risk of developing this type of cancer [93].
Moreover, it was estimated a 35% lifetime risk of developing
pancreatic cancer for patients with HP notedly those bearing
the R122H mutation [94]. Screening HP patients for pancre-
atic cancer has been advocated and should be performed with
pancreatic magnetic resonance imaging and/or endoscopic ul-
trasound in experienced centers. This surveillance should be
initiated at age [50] years or 10 years younger than the earliest
age of pancreatic cancer in the family [95]. Furthermore, in
HP symptomatic patients, genetic testing is justified aiming to
clarify etiology and provide genetic counseling [16].
DEP appears to share a similar risk for the micro and
macro-vascular complications observed in T1DM [66]. This
risk is diminished by a good glycemic control. GV, higher in
DEP than in type 2 diabetes, is considered an independent risk
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for these complications [96]. Further studies are needed to
endorse the association with higher rates of vascular compli-
cations. Therefore, these patients should be monitored follow-
ing the same guidelines proposed for type 1 and 2 DM [50••].
Conclusion
In summary, this study contributes to the characterization of
diabetes mellitus in the context of disease of the exocrine
pancreas related to hereditary pancreatitis. Nevertheless, more
surveys are required to establish practicable clinical diagnostic
criteria, as the lack of this feature carries us into a mis- and
underdiagnosing scenario. A clinical suspicion of DEP due to
HP should instigate investigation, since the correct diagnosis
allows an effective assistance of these patients, recommending
precise and needed treatments as well as preventing severe
complications. Furthermore, we believe that this article has
high clinical relevance, seeing that reviews HP endocrine out-
comes and detailing novel diagnostic and treatment features
about the theme.
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